Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

por Dizman, Nazli, Meza, Luis, Bergerot, Paulo, Alcantara, Marice, Dorff, Tanya, Lyou, Yung, Frankel, Paul, Cui, Yujie, Mira, Valerie, Llamas, Marian, Hsu, Joann, Zengin, Zeynep, Salgia, Nicholas, Salgia, Sabrina, Malhotra, Jasnoor, Chawla, Neal, Chehrazi-Raffle, Alex, Muddasani, Ramya, Gillece, John, Reining, Lauren, Trent, Jeff, Takahashi, Motomichi, Oka, Kentaro, Higashi, Seiya, Kortylewski, Marcin, Highlander, Sarah K., Pal, Sumanta K.
Publicado 2022

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group

por Abreu, Diego, Carvalhal, Gustavo, Gueglio, Guillermo, Tobia, Ignacio, Garcia, Patricio, Zuñiga, Alvaro, Meza, Luis, Bengió, Rubén, Scorticati, Carlos, Castillejos, Ricardo, Rodriguez, Francisco, Autran, Ana María, Gonzales, Carmen, Gadu, Jose, Nolazco, Alejandro, Ameri, Carlos, Zampolli, Hamilton, Langenhin, Raúl, Muguruza, Diego, Machado, Marcos Tobías, Mingote, Pablo, Yandian, Juan, Clavijo, Jorge, Nogueira, Lucas, Clark, Omar, Secin, Fernando, Rovegno, Agustín, Vilas, Ana, Barrios, Enrique, Decia, Ricardo, Guimarães, Gustavo, Glina, Sidney, Pal, Sumanta K., Rodriguez, Oscar, Palou, Joan, Spiess, Philippe, Lara, Primo N., Linehan, W. Marston, Pastore, Antonio Luigi, Zequi, Stenio C.
Publicado 2021